Status: Recruiting
Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated Pain
A phase 3 study to evaluate the efficacy and safety of HMI-115 in women with moderate to severe endometriosis-associated pain over a 24-week treatment period and a 28-week extension
Participants needed: 540
Trial details
Phase: Phase 3Age: 18-49Biological sex: FemaleType: InterventionalSponsor: Hope Medicine (Nanjing) Co., LtdUpdated: Aug 11, 2026Locations: 5
Eligibility criteria
1. Premenopausal female subjects, between 18 and 49 years of age, inclusive. [+7]
1. Subject who is pregnant or breastfeeding or is planning a pregnancy during th... [+22]